We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| RadNet Inc | NASDAQ:RDNT | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 1.68 | 3.14% | 55.25 | 52.52 | 57.33 | 55.5399 | 53.11 | 53.82 | 639,283 | 23:30:56 |
From May 2022 to May 2024
By Stephen Nakrosis
RadNet Inc. on Monday said its Quantib B.V. subsidiary received 510(k) clearance from the Food and Drug Administration for the third-generation release of its Quantib Prostate MRI artificial intelligence software.
RadNet said the software offers a suite of tools to improve reporting quality and speed, including AI-based segmentations, one-click segmentation of lesion candidates, and standardized reporting. The upcoming will include an improved prostate and sub-region segmentation algorithm, among other functionalities, the company said.
Section 510(k) of the Food, Drug and Cosmetic Act requires manufacturers to give the FDA 90 days advance notice before they can market a medical device.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
May 01, 2023 07:00 ET (11:00 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year RadNet Chart |
1 Month RadNet Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
